sb 216763 has been researched along with Alzheimer Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, S; Bergh, M; Bhat, R; Hellberg, S; Högdin, K; Jerning, E; Lo-Alfredsson, Y; Neelissen, J; Nilsson, Y; Ormö, M; Söderman, P; Tucker, J; von Berg, S; Weigelt, T; Xue, Y | 1 |
| Alam, MS; Hamid, H; Khan, I; Tantray, MA | 1 |
| Bartolini, M; Bolognesi, ML; Campillo, NE; Castellano, S; Feoli, A; Gandini, A; Legname, G; Martinez, A; Martinez-Gonzalez, L; Miti, A; Moda, F; Monti, B; Perez, C; Petralla, S; Roca, C; Rossi, M; Tedesco, D; Zaldivar-Diez, J; Zuccheri, G | 1 |
| Arribas, RL; Belluti, F; Bisi, A; Budriesi, R; Castellano, S; de Los Rios, C; Feoli, A; Gobbi, S; Micucci, M; Rampa, A | 1 |
| Chen, L; Chen, Y; Duan, Y; Feng, F; Huang, J; Jiang, X; Liu, C; Liu, W; Qu, W; Sun, H; Wang, Y; Zhou, J | 1 |
| Chen, T; Chen, Y; Feng, F; Jiang, X; Li, Q; Liu, C; Liu, W; Lyu, W; Sun, H; Wang, S; Wang, Y; Xing, C | 1 |
| Feng, F; Jiang, X; Li, Y; Lin, T; Liu, C; Liu, W; Lyu, W; Sun, H; Xie, H; Xu, J; Zou, M | 1 |
| Chen, P; Chen, S; Deng, Y; Wei, J; Xiong, Z; Yan, Z | 1 |
| Beech, BH; Beech, WK; Begum, AN; Chen, P; Cole, GM; Davies, P; Frautschy, SA; Hu, S; Jones, MR; Kim, PC; Ma, Q; Oh, MS; Ubeda, OJ; Yang, F | 1 |
| Shi, J; Tian, M; Xie, W; Zhu, D | 1 |
1 review(s) available for sb 216763 and Alzheimer Disease
| Article | Year |
|---|---|
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Topics: Alzheimer Disease; Animals; Bipolar Disorder; Clinical Trials as Topic; Diabetes Mellitus; Drug Discovery; Glycogen Synthase Kinase 3; Humans; Models, Molecular; Neoplasms; Patents as Topic; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2017 |
9 other study(ies) available for sb 216763 and Alzheimer Disease
| Article | Year |
|---|---|
Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.
Topics: 3T3 Cells; Alzheimer Disease; Animals; Blood-Brain Barrier; Caco-2 Cells; Cattle; Crystallography, X-Ray; Drug Design; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Models, Molecular; Molecular Structure; Permeability; Phosphorylation; Pyrazines; Solubility; Sulfonamides; tau Proteins | 2012 |
Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Central Nervous System Agents; Circular Dichroism; Drug Design; Drug Evaluation, Preclinical; Fluorescence Resonance Energy Transfer; Glycogen Synthase Kinase 3; Hep G2 Cells; Humans; Microscopy, Atomic Force; Molecular Targeted Therapy; Okadaic Acid; Phosphorylation; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; Swine; tau Proteins; Thiazolidinediones | 2018 |
Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Calcium Channels, N-Type; Glycogen Synthase Kinase 3 beta; Humans; Maleimides; Polycyclic Compounds; Structure-Activity Relationship | 2019 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Glycogen Synthase Kinase 3; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Morris Water Maze Test; Phosphorylation; Protein Conformation; tau Proteins; Thiazoles | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Glycogen Synthase Kinase 3 beta; Humans; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 2021 |
Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in th
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Brain; Cholinesterase Inhibitors; Drug Design; Glycogen Synthase Kinase 3 beta; Humans; Intestines; Mice; Mice, Inbred ICR; Molecular Dynamics Simulation; Neuroprotective Agents; Niacinamide; Protein Kinase Inhibitors; Structure-Activity Relationship; Up-Regulation | 2021 |
β-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Glycogen Synthase Kinase 3; Indoles; Male; Maleimides; Mice; Mice, Transgenic; Molecular Targeted Therapy; N-Methylaspartate; Neuronal Plasticity; Neurons; rab5 GTP-Binding Proteins; Rats; Receptors, N-Methyl-D-Aspartate | 2014 |
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cells, Cultured; Disease Models, Animal; DNA Fragmentation; Enzyme Inhibitors; Gliosis; Glycogen; Glycogen Synthase Kinase 3; Hippocampus; Indoles; JNK Mitogen-Activated Protein Kinases; Maleimides; Maze Learning; Nerve Degeneration; Neurons; Phosphorylation; Rats; Rats, Sprague-Dawley; tau Proteins | 2009 |
Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.
Topics: Alzheimer Disease; Angiotensin II; Animals; Brain; Cognition; Dose-Response Relationship, Drug; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Indoles; Losartan; Male; Maleimides; Phosphorylation; Propranolol; Rats; Rats, Sprague-Dawley; Signal Transduction; tau Proteins | 2012 |